newsfilter
← Latest News
Business Wire·

Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates

— Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end — First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer — Company changed name to Faeth Therapeutics,